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E-mail: christina.orasch@hirslanden.chWe read with interest the Note by Micol et al. [1] challenging
ECIL’s recommendation to discontinue empirical antibiotics
after resolution of fever of unknown origin (FUO) in high-riskClinical Microbiology and Infection © 2014 European Society of Chaematologic patients despite persistent neutropenia. We
reply for the ECIL panel, whose guidance states that
empiric antibiotics can be discontinued after 72
hours . . . in [FUO] patients who have been hemo-
dynamically stable since presentation and . . . afebrile
for48 hours, irrespective of their neutrophil count
or expected duration of neutropenia (BII). The pa-
tient should be kept hospitalized under close
observation for at least a further 24–48 h if (s)he is
still neutropenic when antibiotic therapy is stopped.
If fever recurs, antibiotics should be re-started ur-
gently. . . . Centers that give prophylactic antibacte-
rial agents should consider renewing this regimen
upon discontinuation of the empiric therapy, if the
patient is still neutropenic (CIII).
Micol et al. prospectively evaluated the impact of discontinuing
empirical antibacterial therapy in high-risk acute myeloid
leukaemia patients with FUO in a French university hospital when
all the following criteria were fulﬁlled: (a) 7 days of antibiotics
and5 apyrexial days, (b) clinically stable, (c) no severe systemic
inﬂammation, iv) no microbiologically or clinically documented
infection, (d) no faecal Enterobacteriaceae with extended-
spectrum or AmpC β-lactamases and (e) no intensive care unit
admission, stem cell transplantation, corticosteroids, selective
gut decontamination or systemic antibiotic prophylaxis.
During 7 months, 38 acute myeloid leukaemia patients had
59 febrile episodes, only 7 (12%) of which were followed by
antibiotic discontinuation. Fever recurred within 2 to 3 days in
three of these seven patients, who had received antibiotics for 8
to 11 days. Two relapses involved gram-negative bacteraemia
and one was complicated by septic shock. The 4 patients who
did not experience relapse recovered from neutropenia within
2 to 4 days, after 15 to 29 days of antibiotic treatment. Micol
et al. assert that ECIL’s guidance (a) is insufﬁciently supported
by the literature, (b) minimally reduced antibiotic use (median 3
days reduction in the 12% of patients eligible) and (c) is unsafe.
We refute these criticisms on the following grounds.
Firstly, Micol et al. added extremely restrictive criteria for
discontinuation, not from ECIL’s guidelines (e.g. lack of resistant
fecal Enterobacteriaceae).We assume that they sought to exclude
high-risk patients, but there is no evidence that such patients have
worse outcomes, as long as appropriate empirical antibiotics are
restarted immediately if fever relapses. Moreover, their require-
ment for7 days of antibiotic therapy and5 days without fever
exceeds ECIL-4’s recommendations (72 and 48 hours,
respectively). These differences doubtless militated against sub-
stantial reductions in antibiotic use. It is unclear why the seven
patients whose antibiotics were stopped ‘early’ nevertheless
received a median of 15 days of antibiotics, nor why bothClin Microbiol Infect 2015; 21: e25–e27
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nation (to prevent colonization) were exclusion criteria.
Secondly, Micol et al. highlight high relapse and bacteremia
rates among patients whose antibiotics were discontinued. We
understand their concerns, but the numbers are small and no
patient died, suggesting that antibiotics were successfully restar-
ted immediately after fever recurred, as ECIL-4 advocates. They
omit the relapse rate among patients who continued receiving
antibiotics, though a rate of three of seven patients compares
with their overall rate of 1.5 febrile episodes per patient (59
episodes in 39 patients). Table 1 summarizes randomized and
observational studies [2] regarding stopping or continuing anti-
biotics after resolution of FUO in high-risk haematologic patients.
Recurrence of fever was frequent when neutropenia persisted,
regardless of the continuation of antibiotics. Moreover, second-
ary infections/fevers have signiﬁcantly increased mortality
compared with primary infections or fever [3].
Thirdly, the arguments of Micol et al. assume that there is no
harm in continuing antibiotics in persistent neutropenia. We
disagree. Prolonged treatment drives gut colonization with
resistant pathogens, which is a risk factor for difﬁcult-to-treat
breakthrough infections. With 1.5 infective episodes per case,
this selection is a risk for the immediate patient, as well as for
future patients in the unit. We particularly question continuing
antibiotics in patients otherwise eligible for discontinuation
‘because they were colonized with β-lactamase-producing
bacteria.’ Surely continuation, which is likely to drive coloni-
zation, is the hazard here, not discontinuation. Known coloni-
zation should inform treatment choice if fever recurs, but it is
not a reason for denying discontinuation.
Lastly, Micol et al. challenge the quality of studies on which
ECIL-4 based the guidelines. By grading these recommendationsTABLE 1. Relapse and death after discontinuation vs. continuation o
neutropenia after resolution of FUO in high-risk hematologic patie
Study Year Design
Duration of
neutropenia
Pizzo et al. 1979 Open randomization:
continue vs. stop
antibiotics
12 days (median)
Joshi et al. 1984 Observational 20.5 days (mean)
Pizzo et al. 1987 Observational >14 days
Cornelissen et al. 1995 Observational 7 days (median)
Horowitz et al. 1996 Observational 17 days (mean)
Santolaya et al. 1997 Open randomization:
continue vs. stop
antibiotics
9 days (mean)
IDG-EORTC—Cometta et al.
and Viscoli et al. (unpublished)
2003
2006
Post hoc observational
analysis
17.5 days (median)
Cherif et al. 2004 Observational NA
Slobbe et al. 2009 Observational 20.5 days (mean)
FUO, fever of unknown origin; NA, not analysed or not applicable.
aSecondary ciproﬂoxacin prophylaxis.
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the panel considers that recurrence of fever is not a strong
predictor of severe infectious complications or death, provided
there is close follow-up, with immediate reinitiation of antibac-
terial therapy if fever recurs. Our guidelines, endorsed by the
European Society of Clinical Microbiology and Infectious Dis-
eases and its Study Group for Infections in Compromised Hosts,
concur with one option suggested by the Infectious Diseases
Society of America: to stop intravenous antibiotics after reso-
lution of FUO and before neutrophil recovery. IDSA suggest
that this should be combined with secondary ﬂuoroquinolone
prophylaxis (CIII). ECIL-1 (2005) advocated primary ﬂuo-
roquinolone prophylaxis, but ECIL-4 avoided recommendations
on secondary prophylaxis as a result of the proliferation of ﬂu-
oroquinolone resistance in bloodstream isolates in parts of
Europe [4]. Primary or secondary ﬂuoroquinolone prophylaxis
should be considered only in locations with low resistance rates,
suggested to be 20% resistance in gram-negative bacteria and
50% overall [5]. Although many centers do not apply any
preventive approach, others use oral ﬂuoroquinolones and/or
selective gut decontamination. No speciﬁc data are available to
stratify the risk of stopping antibiotics in leukemic patients un-
dergoing induction vs. salvage vs. consolidation chemotherapy
or in allogeneic vs. autologous stem cell transplant recipients.
Toxic disruption of the mucosal barrier is a major risk factor for
bacterial translocation, and caution is needed in stopping anti-
biotics before severe mucositis resolves.
In conclusion, after careful assessment of the interesting, but
small and single-center, observations of Micol et al., the ECIL-4
panel conﬁrms its recommendation for antibiotic discontinua-
tion despite persistent neutropenia after resolution of FUO.
This approach is effective, safe and ethical, provided thatf intravenous empirical antibacterial therapy during persistent
nts
Continuation of
antibacterial therapy
Discontinuation of antibacterial
therapy during persistent neutropenia
Relapsing
neutropenic
fever
Death due to
bacterial
infection
Relapsing
neutropenic fever
Death due to
bacterial infection
1/16 (6%) 0 (0%) 7/17 (41%) 2/17 (12%)
NA NA 8/16 (50%) 0 (0%)
35/93 (38%) 3/95 (3%) NA NA
NA NA 7/85 (8%) 2/85 (2%)a
NA NA 3/10 (33%) 0 (0%)
3/39 (8%) 0 (0%) 2/36 (6%) 0 (0%)
49/114 (43%) 1/114 (1%) NA NA
NA NA 9/49 (18%) 0 (0%)
NA NA NR 1/169 (0.5%)a
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initiated if fever relapses. The strategy reduces antibiotic usage
and selection pressure for resistance at both the individual and
unit levels. This is critical to maintaining our ability to treat
infections in haematology patients.Transparency declarationAll authors report no conﬂicts of interest relevant to this
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